| Scorecard |
|---|
|
3 / 5 Stars
|
|
Lipper
4
5
5
5
4
|
|
Zacks Investment Research
2
(Buy)
|
|
Standard & Poor's
4 / 5 Stars
|
|
TheStreet.com
A+
(Buy)
|
U.S. News evaluated 38 Health Funds. Our list highlights the top-rated funds for long-term investors based on the ratings of leading fund industry researchers.
Performance
The fund has returned 27.13 percent over the past year, 18.17 percent over the past three years, 9.78 percent over the past five years, and 10.22 percent over the past decade.
| Trailing Returns | Updated 04.30.2013 |
|---|---|
| Year to date | 19.1% |
| 1 Year | 27.1% |
| 3 Years (Annualized) | 18.2% |
| 5 Years (Annualized) | 9.8% |
| 10 Years (Annualized) | 10.2% |
Summary
The investment seeks long-term growth of capital. The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets in securities of companies that the portfolio manager believes have a life science orientation. Generally speaking, the "life sciences" relate to maintaining or improving quality of life. It normally invests at least 25% of its total assets in the "life sciences" sector, which may include companies in the following industry groups: health care; pharmaceuticals; agriculture; cosmetics/personal care; and biotechnology.
Fees
Fees are Low compared to funds in the same category.
Janus Global Life Sciences Fund has an expense ratio of 1.83 percent.
Risk
Risk is Average compared to funds in the same category according to Morningstar.
